Pascal Soriot, Chief Executive Officer, AstraZeneca, said ... our two large R&D sites in Gaithersburg MD and Cambridge MA. Overall, we are making excellent progress toward our ambition of ...

AstraZeneca AZN1.38%increase; green up pointing triangle posted increased core earnings per share and sales for the first quarter but warned of mounting legal challenges in China. The British ...

China In April 2025, there are following developments in relation to the China investigations: First, in relation to the illegal drug importation allegations, AstraZeneca received an Appraisal ...

AstraZeneca has doubled down on plans to grow its US business as it braces for the country’s potential tariffs on the pharmaceutical industry. The drug maker said it is “firmly committed to ...

AstraZeneca has axed three MedImmune legacy monoclonal antibody drugs from its neuroscience pipeline in a first-quarter clear-out. The Anglo-Swedish Big Pharma announced in its first-quarter ...

AstraZeneca has 11 production sites in the U.S. covering small molecules, biologics as well as cell therapy. It also has two large R&D sites in Gaithersburg MD and Cambridge MA.” Guidance ...

British pharmaceutical giant AstraZeneca announced Tuesday that it has begun moving some of its European production to the United States, ahead of President Donald Trump's possible tariffs on the ...

AstraZeneca has come up short in another phase 3 trial of the AKT inhibitor Truqap, raising more questions about the blockbuster potential of the first-in-class cancer treatment. Alongside its ...

The United States is a key market for the pharmaceutical industry, and AstraZeneca had already planning to invest $3.5 billion there by the end of 2026. Soriot said earlier in the year that he ...

LONDON, April 29 (Reuters) - The chief executive of AstraZeneca (AZN.L), opens new tab said on Tuesday that the drugmaker will maintain its 2025 sales guidance even if the U.S. levies tariffs on ...

AstraZeneca Plc’s Chief Executive Officer Pascal Soriot warned that trade tariffs are not the best way to manage pharmaceuticals and that drugmakers are calling for no additional US levies on ...

LONDON (Reuters) -The chief executive of AstraZeneca said on Tuesday that the drugmaker will maintain its 2025 sales guidance even if the U.S. levies tariffs on pharma products made in the ...